NCT03963518View on ClinicalTrials.gov

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

CompletedOBSERVATIONAL

Enrollment

631

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Cancer Treated With Immune-checkpoint Inhibitors

Interventions

DRUG

nivolumab monotherapy

nivolumab monotherapy

DRUG

nivolumab plus ipilimumab

nivolumab plus ipilimumab

Trial Locations (1)

Unknown

Institut Bergonié, Comprehensive Cancer Center, Bordeaux

Sponsors

Lead Sponsor

Institut Bergonié

All Listed Sponsors

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

Institut Bergonié

OTHER